View More
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
Results from subgroup analysis analyzing the efficacy, safety of dupilumab with or without concomitant TCS in patients with erythrodermic AD, from CCO
Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO
Efficacy, safety of once-daily oral abrocitinib 200 mg and 100 mg vs placebo in patients aged ≥12 years with moderate to severe AD; atopic dermatitis conference coverage from CCO
An investigation of the efficacy and safety of dupilumab and concomitant topical corticosteroids in children aged ≥ 6 to < 12 years with severe AD: atopic dermatitis conference coverage from CCO
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.